Ben Liu
@BenjamineYLiu
Followers
2K
Following
518
Media
7
Statuses
103
co-founder and CEO @formationbio
New York
Joined September 2014
Excited to welcome Danny Neil (CTO, previously CTO at @benevolent_ai ), Lou Brenner (CMO), Frank D'Amelio (Sr. Advisor, previously CFO at @pfizer), Dash Dhanak (Sr. Advisor, previously CSO at @Incyte) to our team at @formationbio. Read more below: https://t.co/fi4SbJlKZs
0
2
8
Congrats to several Thermal clients recognized by BioSpace! 👏 Read about their ongoing achievements, from advancing #CRISPR to #AI for drug discovery and clinical trials, below. @enfeinberg, CEO of Genesis Therapeutics https://t.co/MrEdA4UOmW
@BenjamineYLiu, CEO of
biospace.com
Genesis Therapeutics
Introducing BioSpace’s 2025 40 Under 40 Winners! ✨ Congratulations to our inaugural cohort. These young leaders hail from a range of business functions and highlight the values 40 Under 40 is designed to celebrate. BioSpace’s 40 Under 40 honors 40 exemplary biotech and pharma
0
1
2
Proud to see @BenjamineYLiu recognized in @BioSpace’s 40 Under 40 this year! Read the full write-up here:
biospace.com
Formation Bio
0
2
4
Congrats to Thermal clients @formationbio (using AI to clear the clinical trial bottleneck and make studies more affordable) and Georgiamune (targeting T cell master switches to reprogram immune behavior). đź‘Źđź‘Ź
Introducing Fierce Biotech’s 2025 class of Fierce 15 winners. From advancing radically new therapies to refining existing modalities, this year’s companies are pushing the envelope and giving us a reason for optimism.
0
1
2
Thanks @FierceBiotech for including @formationbio amongst our industry's 15 most innovative companies.
1
0
10
Three new additions to the Deus Ex Medicina roster @zackmziegler, founder and CTO of OpenEvidence @janiceschen, founder and CTO of Mammoth Biosciences @BenjamineYLiu, founder and CEO of Formation Bio We'll be hosting the summit on Tuesday in SF
1
2
4
Coming up next week in SF: @formationbio Co-Founder & CEO @BenjamineYLiu will be speaking at @EricNewcomer's AI Health & Longevity Summit, where he'll be discussing all things AI + drug development.
0
4
10
Excited to share an update at @formationbio: We’ve added @Imidomics first-in-class anti-CD226 antibody to our pipeline — a Phase 1–ready program for Ulcerative Colitis. Grateful to Fred Craves & Sandy Zweifach for the collaboration and shared vision for the program’s future.
@IMIDomics discovered the initial science, and now @formationbio is taking it forward to clinical development. Today we announced our license of IMIDomics' first-in-class, Phase-1 ready anti-CD226 antibody targeting Ulcerative Colitis. Go behind the scenes with both teams here.
4
8
66
Enjoyed chatting with the team @a16z and @Techweek_. Not sure that Art Levinson (now @calico) remembers our call, but his advice left an indelible impact on how we think about mission, values, and cultural inertia.
If you’re building for 10+ years, “just get started” won’t cut it. @BenjamineYLiu (CEO/cofounder of @formationbio ) says: ask the counterfactual. Would the world be any different if your company didn’t exist? If not, go back to the whiteboard.
0
1
9
Congrats to @sanofi and @formationbio on the start of a great partnership
Excited to announce our license of Gusacitinib to @sanofi for upwards of €545M in upfront and milestones in addition to royalties in the low to mid-teen based on future sales.
1
1
16
So grateful for the team at @formationbio for all the incredible work and our collaborators at @sanof, Asana BioSciences and @Tarsadia_Inv for the partnership on this program.
0
0
4
In the long run, we plan to go end-to-end, leveraging our AI systems to develop and commercialize our own drugs to transform the speed, efficiency, and accessibility of drugs to patients.
1
0
5
This is a meaningful proof point for @formationbio on our journey to create this generation’s AI native company. In the short term, our business model involves partnering or selling drug assets back to pharma after key value inflection points.
1
0
8
Excited to announce our license of Gusacitinib to @sanofi for upwards of €545M in upfront and milestones in addition to royalties in the low to mid-teen based on future sales.
14
4
100
This is a meaningful proof point for @formationbio on our journey to create this generation’s AI native company. In the short term, our business model involves partnering or selling drug assets back to pharma after key value inflection points.
0
0
2
Thanks @CNBC @CNBCFastMoney for having me on!
A disruptor in the AI drug discovery space... @formationbio's @BenjamineYLiu explains how his company is using AI in drug development and what's next for a quickly evolving space https://t.co/ljcqG7caFc
0
0
4